This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Case Report

Cytochrome P450 2D6 Polymorphism and Its Impact on Decision-Making in Psychopharmacotherapy: Finding the Right Way in an Ultrarapid Metabolizing Patient

Michael Paulzen, MD; Simone C. Tauber, MD; André Kirner-Veselinovic, MD; and Gerhard Gründer, MD

Published: November 15, 2011

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The cytochrome P450 (CYP) superfamily represents the most important phase I drug metabolizing enzyme system. Genetic mutations play an important role in the activity especially of CYP2D6. Genetic polymorphisms within CYPs affect the metabolism of drugs as substrates for the particular enzymes, resulting in variations in plasma levels of the drugs, differences in drug response, or altered risk for adverse effects.

Volume: 72

Quick Links: Assessment Methods , Genetics

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...